Ein Gewichtsverlustmedikament wird von Pfizer entsorgt.

Published Date: 01 Jul 2023

Due to concerns about the safety of the drug for the liver, Pfizer announced it is discontinuing the once-daily experimental obesity medication, but it will continue to develop the twice-daily danuglipron.

Read Full News

Latest News

Finding the Next Weight-Loss Drug in Python Blood

Pythons can go weeks without eating. Now researchers have isolated an appetite-suppressing metabolite in python blood that could spur a new weight-loss therapy.

Diabetes Meds Show Varied Associations With Liver Protection

Different antidiabetic drug classes show distinct associations with the risk for major adverse liver outcomes among patients with type 2 diabetes, according to a network meta-analysis.

Could Digital Obesity Care Help Improve the Economy?

A UK digital obesity programme was associated with > 40% fewer GP visits and markedly lower long-term sick leave within 9 months in a real-world analysis.

CGM Reduces Complications, Mortality in T1D

Continuous glucose monitoring was associated with substantial reductions in diabetes-related complications and mortality in adults with type 1 diabetes in a large national study.

A Practical Guide to Make Digital Tools Work With GLP-1s

The learning curve can be steep for patients trying apps, wearables, and telehealth platforms. Your expertise is needed.

Diabetes Linked to Increased Cancer Risk in Hispanic Adults

Researchers determine time-varying diabetes measures and cancer incidence over time from a US multisite, prospective cohort study involving 16,415 Hispanic and Latino adults aged 18-74 years.

Todays Updates

NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

A nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.

Less Mental Decline With Darolutamide vs Enzalutamide in PC

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Todays Updates

NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

A nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.

Less Mental Decline With Darolutamide vs Enzalutamide in PC

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Latest News

Pythons can go weeks without eating. Now researchers have isolated an appetite-suppressing metabolite in python blood that could spur a new weight-loss therapy.

Different antidiabetic drug classes show distinct associations with the risk for major adverse liver outcomes among patients with type 2 diabetes, according to a network meta-analysis.

A UK digital obesity programme was associated with > 40% fewer GP visits and markedly lower long-term sick leave within 9 months in a real-world analysis.

Continuous glucose monitoring was associated with substantial reductions in diabetes-related complications and mortality in adults with type 1 diabetes in a large national study.

The learning curve can be steep for patients trying apps, wearables, and telehealth platforms. Your expertise is needed.

Researchers determine time-varying diabetes measures and cancer incidence over time from a US multisite, prospective cohort study involving 16,415 Hispanic and Latino adults aged 18-74 years.

News All Time

New Dosing Option Okayed for X-Linked Hypophosphatemia Drug

The FDA has approved an option to increase the dose and frequency of burosumab-twza for adults whose serum phosphorus remains below normal.

BioMarin's Genetic Disease Therapy Shows Mixed Results in Late-stage Study

BioMarin Pharmaceutical said on Monday its experimental treatment for a rare genetic condition met ⁠one of the two main goals in a late-stage study.

Many Parents on Obesity Meds Discuss Treatment With Kids

Parents often discuss using obesity medications and related weight or behavior changes with their children.

Menopause Symptoms Worse in Women With Abdominal Obesity

Women with abdominal obesity report a higher burden of certain menopausal symptoms and exhibit a distinct pattern of symptom interrelationships relative to women without abdominal obesity.

Can Lower-Dose Tirzepatide Keep Weight Off?

New trial data suggest some patients may maintain meaningful weight loss after stepping down from the maximum dose of tirzepatide.

Pesticides May Help Explain Rising Early-Onset CRC Rates

A study linked a common herbicide to rising early-onset colorectal cancer, using DNA methylation to trace lifelong exposures rather than relying on patient recall.

Restarting GLP-1s After Stopping: How to Counsel Patients

Many patients taking GLP-1 RAs for weight loss discontinue within the first year. How can clinicians support long-term success with these drugs?

Exclusive-FDA Drug Center Head Expected to Leave After Commissioner's Exit, Sources Say

The acting head of the U.S. Food and Drug Administration's drug center, Tracey Beth Hoeg, is expected to leave the agency just days after Commissioner Marty ⁠Makary...

US Cancer Clinics Scramble to Get Experimental Revolution Medicines Pancreatic Cancer Drug

U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from Revolution Medicines while they await...

Implanted Islet Cell Device Could Control Glucose for Weeks

Researchers developed a battery-free device the size of a coin that can deliver islet cells in the body and keep them healthy, no immunosuppression required.

Can GLP-1 Drugs Improve Breast Cancer Survival?

A ‘big’ data study links the diabetes and weight-loss drugs to better long-term survival after breast cancer. Critics are unconvinced.

Blame for the Obesity Epidemic Falls on Food Industry

The rise of new weight-loss drugs could help reframe obesity as a societal failure driven by the food industry, rather than an individual failing rooted in lack of willpower.

EyePoint's Late-stage Eye Drug Trials to Continue After Safety Panel Review

EyePoint said on Thursday an independent safety committee found no new concerns in two late-stage trials ⁠of its experimental eye disease drug Duravyu and recommended the...

Can Gut Bacterium Supplement Lead to Less Weight Regain?

Daily supplementation with pasteurized Akkermansia muciniphila MucT after weight loss leads to less weight regain than placebo in adults with overweight or obesity.

Stress, BMI Linked to Earlier Puberty in Girls

Higher levels of non-estrogen hormones, along with stress and elevated BMI, are linked to earlier breast development in girls.

Did Hyperglycemia Affect Inavolisib-Efficacy in BC Patients?

Exploratory data show inavolisib benefits persist regardless of hyperglycemia in PIK3CA-mutated breast cancer, with numerically better outcomes among patients who develop the metabolic side effect.

Recommended News For You

Bladder cancer link to explosive ordnance exposure among Army veteran bomb disposal officers

Survivors of high-risk neuroblastoma face substantial late effects of modern therapies

Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

HER2 ADC Shows Promise in Recurrent Endometrial Cancer

Antitumor cell activity in glioblastoma is controlled by blocking the triggering receptor expressed on myeloid cells 2.

Inner Thoughts of Leonard Bernstein, the "Maestro".

Recommended Articles For You

The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring 

Exosomes in Cancer: A Novel Frontier for Therapy and Biomarker Discovery 

Exploring the Latest Treatments for Essential Thrombocythemia 

Unraveling the Mystery of Non-Caseating Granulomas: A Comprehensive Guide 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

2.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

3.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

4.

According to a study, taking part in a clinical trial for cancer may not actually increase survival.

5.

A new blood test greatly increases the ability to detect cancer.

1.

Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis

2.

Unraveling the Mysteries of Hematocrit: How It Impacts Your Health

3.

The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers

4.

Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer

5.

Surprising Symptoms of Prostate Cancer: What You Need to Know

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part X

2.

Efficient Management of First line ALK-rearranged NSCLC - Part III

3.

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

4.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

5.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot